Randomized, comparative study of interferon β-1a treatment regimens in MSHillel Panitch, Brian G. Weinshenker, Monaghan Ed et al.|Neurology|2002Cited by 633
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D. Mikol, Bernard M.J. Uitdehaag, Bettina Stubinski et al.|The Lancet Neurology|2008Cited by 484
Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trialHillel Panitch, Brian G. Weinshenker, Douglas S. Goodin et al.|Journal of the Neurological Sciences|2005Cited by 98